
Quarterly report 2025-Q3
added 04-25-2026
Autolus Therapeutics plc Net Debt 2011-2026 | AUTL
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Autolus Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.7 M | -175 M | -187 M | -358 M | - | - | - | - | -137 M | -27.9 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -27.9 M | -358 M | -153 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
-7.95 M | - | -19.68 % | $ 18.4 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.9 | -2.33 % | $ 6.62 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 21.96 | -0.68 % | $ 3.64 B | ||
|
RedHill Biopharma Ltd.
RDHL
|
53.8 M | $ 1.02 | -0.49 % | $ 428 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Aligos Therapeutics
ALGS
|
-132 M | $ 6.4 | 4.4 % | $ 63.3 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 21.41 | 1.9 % | $ 1 B | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
Kazia Therapeutics Limited
KZIA
|
-5.43 M | $ 12.26 | 3.72 % | $ 1.62 B | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
-973 M | $ 105.46 | -0.09 % | $ 27.2 B | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.08 | 0.25 % | $ 436 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 23.26 | 1.75 % | $ 2.96 B | ||
|
Cara Therapeutics
CARA
|
-20.5 M | - | -3.03 % | $ 260 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
BioXcel Therapeutics
BTAI
|
56.3 M | $ 1.06 | -3.64 % | $ 12.9 M | ||
|
CASI Pharmaceuticals
CASI
|
-36.5 M | - | - | $ 35.4 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Cabaletta Bio
CABA
|
-76.6 M | $ 2.95 | -3.28 % | $ 296 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.91 | -1.36 % | $ 4.79 M | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B |